RemeGen Co. Ltd
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for … Read more
RemeGen Co. Ltd (REGMF) - Total Liabilities
Latest total liabilities as of September 2025: $3.66 Billion USD
Based on the latest financial reports, RemeGen Co. Ltd (REGMF) has total liabilities worth $3.66 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
RemeGen Co. Ltd - Total Liabilities Trend (2018–2024)
This chart illustrates how RemeGen Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
RemeGen Co. Ltd Competitors by Total Liabilities
The table below lists competitors of RemeGen Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eco World Develop Group
KLSE:8206
|
Malaysia | RM7.37 Billion |
|
Dashang Co Ltd
SHG:600694
|
China | CN¥8.30 Billion |
|
Daheng New Epoch Technology Inc
SHG:600288
|
China | CN¥989.82 Million |
|
Shandong Weida Machinery Co Ltd
SHE:002026
|
China | CN¥931.92 Million |
|
Kaili Catalyst & New Materials Co. Ltd. A
SHG:688269
|
China | CN¥1.03 Billion |
|
Shenzhen Jinjia Color Printing Group Co Ltd
SHE:002191
|
China | CN¥1.62 Billion |
|
YG Entertainment Inc
KQ:122870
|
Korea | ₩209.26 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down RemeGen Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.96 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how RemeGen Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for RemeGen Co. Ltd (2018–2024)
The table below shows the annual total liabilities of RemeGen Co. Ltd from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.51 Billion | +67.98% |
| 2023-12-31 | $2.09 Billion | +100.88% |
| 2022-12-31 | $1.04 Billion | +46.03% |
| 2021-12-31 | $712.79 Million | +36.27% |
| 2020-12-31 | $523.07 Million | -43.22% |
| 2019-12-31 | $921.28 Million | -10.49% |
| 2018-12-31 | $1.03 Billion | -- |